1. Home
  2. SCWO vs IPHA Comparison

SCWO vs IPHA Comparison

Compare SCWO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$2.22

Market Cap

43.4M

Sector

Utilities

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.33

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCWO
IPHA
Founded
2021
1999
Country
United States
France
Employees
N/A
163
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
131.4M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
SCWO
IPHA
Price
$2.22
$1.33
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
55.1K
19.7K
Earning Date
05-14-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$215,037.00
N/A
Revenue This Year
$25,798.80
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.18
52 Week High
$3.60
$2.63

Technical Indicators

Market Signals
Indicator
SCWO
IPHA
Relative Strength Index (RSI) 37.93 42.77
Support Level $0.24 $1.18
Resistance Level $3.55 $1.80
Average True Range (ATR) 0.22 0.08
MACD -0.05 -0.01
Stochastic Oscillator 12.79 0.00

Price Performance

Historical Comparison
SCWO
IPHA

About SCWO 374Water Inc.

374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: